title: PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.
abstract: Prescribed in patients with a history of myocardial infarction, stroke, transient ischemic attack, coronary intervention or bypass surgery, aspirin is one of the medications most commonly used in the secondary prevention of cardiovascular diseases. It has become a mainstay of therapy after years of solid evidence supporting its efficacy in clinical trials. However, a number of risks and side effects accompany its benefits, including the notable risk of bleeding and gastrointestinal side effects. Numerous mechanisms have been proposed to attenuate these effects to promote adherence and to expand the population for which aspirin is a reasonable treatment option. A polypill or combination formulation that includes a proton pump inhibitor, a drug commonly prescribed alongside aspirin, is one potential avenue of therapy. One such combination pill, PA32540, has undergone Phase I and Phase III trials and shows promising safety and efficacy results in these preliminary trials.
authors.affiliation: Thomas Jefferson University, Philadelphia, PA 19107, USA.
authors.forename: Danielle
authors.initials: D
authors.lastname: Duffy
authors.forename: Bridget
authors.initials: B
authors.lastname: Rooney
authors.forename: Suzanne
authors.initials: S
authors.lastname: Adams
authors.forename: David J
authors.initials: DJ
authors.lastname: Whellan
mesh_terms: D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D055502:Secondary Prevention; D013276:Stomach Ulcer / Q000150:complications / Q000188:drug therapy
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
keywords: aspirin; cardiovascular disease; omeprazole; polypill; secondary prevention